MITRIS RESILIA Mitral Valve

Designed to handle the pressure of the mitral position
When replacement is the best choice, what if you had an option designed to be similar to the native valve?

When your patient’s disease may be too complex, and mitral valve repair is not feasible, Edwards Lifesciences brings you the MITRIS RESILIA mitral valve.

As your trusted partner in cardiac surgery innovation, Edwards has developed the MITRIS RESILIA mitral valve to help meet the specialized needs of your patients. We understand the mitral valve and that the skill required to repair or replace it commands your respect. That’s why we designed a replacement valve built for the mitral position.
How the MITRIS valve handles the pressure of the mitral position:

**A saddle-shaped** sewing cuff that mimics the native mitral annulus. This asymmetrical design is specifically tailored to the contours of the native annulus.

**RESILIA tissue** is designed to offer enhanced tissue anti-calcification technology and the promise of increased durability.¹

RESILIA tissue is bovine pericardial tissue treated with a special integrity preservation technology that effectively eliminates free aldehydes, a key factor in tissue calcification, while protecting and preserving tissue.¹,²

**Good visibility under fluoroscopy** for easy identification of the landing zone for potential future transcatheter interventions.

**Lowest profile stents** do not obstruct blood flow through the left ventricular outflow tract (LVOT).

Dry storage to **eliminate need** for rinsing.

*No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients.*

Nitinol stents fold down to 55 degrees allowing for ease of implant; stents return to original position when valve is implanted.

We designed the MITRIS RESILIA mitral valve:

> To be conformable and seat well on the mitral annulus
> To be a replacement option similar to the native valve
> To handle the pressure of the mitral position

Learn what the MITRIS valve can do for you and your patients.
Backed by a strong and growing body of clinical evidence supporting RESILIA tissue’s ongoing study of durability and hemodynamic performance.¹⁴⁵⁶

COMMENCE Mitral clinical trial
Clinically stable hemodynamics and one incident of structural valve deterioration (SVD) through 4 years in 82 patients.

**98.7%** Actuarial freedom from SVD through 4 years

COMMENCE Aortic clinical trial
Clinically stable hemodynamics and zero SVD through 5 years in 689 patients.¹

**100%** Actuarial freedom from SVD through 5 years

European Aortic clinical trial
Clinically stable hemodynamics and zero SVD through 5 years in 133 patients.

**100%** Actuarial freedom from SVD through 5 years

¹ SVD diagnosed at post-operative day 1848
Built on the trusted Carpentier-Edwards PERIMOUNT valve platform, and made with RESILIA tissue for decreased calcification*, this is the mitral valve developed with your patient’s quality of life in mind.

Here you have a valve choice designed to handle the pressure of the mitral position.

Talk to your rep or visit edwards.com/mitris to find out more.

* No clinical data are available that evaluate the long-term impact of RESILIA tissue in patients.